SIMCERE PHARMA (02096): Enzastaurin® and Endostar® Included in China's Updated National Reimbursement Drug List

Stock News

Dec 08

SIMCERE PHARMA (02096) announced on December 7, 2025, that Enzastaurin® (Suvizumab for Injection) has been officially included in the updated National Reimbursement Drug List (NRDL) issued by China's National Healthcare Security Administration and Ministry of Human Resources and Social Security. The inclusion will take effect from January 1, 2026. Additionally, Endostar® (Recombinant Human Endostatin Injection) has successfully completed its renewal in the NRDL.

Enzastaurin® is a next-generation recombinant humanized anti-vascular endothelial growth factor (VEGF) monoclonal antibody, approved for marketing in China on June 30, 2025. It is indicated in combination with paclitaxel, liposomal doxorubicin, or topotecan for the treatment of adult patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer who have developed platinum resistance and received no more than one prior systemic therapy.

Endostar®, China's first anti-angiogenic targeted drug and the world's only approved endostatin product, has been included in the NRDL since 2017. It has become one of the cornerstone treatments for advanced non-small cell lung cancer.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1122930304"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1122930304\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1122930304?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-08 07:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1122930304","market":"hk","top_or_hot":-1,"title":"SIMCERE PHARMA (02096): Enzastaurin® and Endostar® Included in China's Updated National Reimbursement Drug List","media":"Stock News","content":"<p>SIMCERE PHARMA (02096) announced on December 7, 2025, that Enzastaurin® (Suvizumab for Injection) has been officially included in the updated National Reimbursement Drug List (NRDL) issued by China's National Healthcare Security Administration and Ministry of Human Resources and Social Security. The inclusion will take effect from January 1, 2026. Additionally, Endostar® (Recombinant Human Endostatin Injection) has successfully completed its renewal in the NRDL.</p>\n<p>Enzastaurin® is a next-generation recombinant humanized anti-vascular endothelial growth factor (VEGF) monoclonal antibody, approved for marketing in China on June 30, 2025. It is indicated in combination with paclitaxel, liposomal doxorubicin, or topotecan for the treatment of adult patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer who have developed platinum resistance and received no more than one prior systemic therapy.</p>\n<p>Endostar®, China's first anti-angiogenic targeted drug and the world's only approved endostatin product, has been included in the NRDL since 2017. It has become one of the cornerstone treatments for advanced non-small cell lung cancer.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SIMCERE PHARMA (02096): Enzastaurin® and Endostar® Included in China's Updated National Reimbursement Drug List</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSIMCERE PHARMA (02096): Enzastaurin® and Endostar® Included in China's Updated National Reimbursement Drug List\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-08 07:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SIMCERE PHARMA (02096) announced on December 7, 2025, that Enzastaurin® (Suvizumab for Injection) has been officially included in the updated National Reimbursement Drug List (NRDL) issued by China's National Healthcare Security Administration and Ministry of Human Resources and Social Security. The inclusion will take effect from January 1, 2026. Additionally, Endostar® (Recombinant Human Endostatin Injection) has successfully completed its renewal in the NRDL.</p>\n<p>Enzastaurin® is a next-generation recombinant humanized anti-vascular endothelial growth factor (VEGF) monoclonal antibody, approved for marketing in China on June 30, 2025. It is indicated in combination with paclitaxel, liposomal doxorubicin, or topotecan for the treatment of adult patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer who have developed platinum resistance and received no more than one prior systemic therapy.</p>\n<p>Endostar®, China's first anti-angiogenic targeted drug and the world's only approved endostatin product, has been included in the NRDL since 2017. It has become one of the cornerstone treatments for advanced non-small cell lung cancer.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"","article_id":"1122930304","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1122930304","pubTimestamp":1765149139,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"SIMCERE PHARMA (02096) announced on December 7, 2025, that Enzastaurin® (Suvizumab for Injection) has been officially included in the updated National Reimbursement Drug List (NRDL) issued by China's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","BK1583":"高瓴概念","02096":"先声药业"},"translate_title":"先声药业(02096)：恩扎妥林®和Endostar®纳入中国更新的国家报销药品目录","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02096":1},"content_text":"SIMCERE PHARMA (02096) announced on December 7, 2025, that Enzastaurin® (Suvizumab for Injection) has been officially included in the updated National Reimbursement Drug List (NRDL) issued by China's National Healthcare Security Administration and Ministry of Human Resources and Social Security. The inclusion will take effect from January 1, 2026. Additionally, Endostar® (Recombinant Human Endostatin Injection) has successfully completed its renewal in the NRDL.\nEnzastaurin® is a next-generation recombinant humanized anti-vascular endothelial growth factor (VEGF) monoclonal antibody, approved for marketing in China on June 30, 2025. It is indicated in combination with paclitaxel, liposomal doxorubicin, or topotecan for the treatment of adult patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer who have developed platinum resistance and received no more than one prior systemic therapy.\nEndostar®, China's first anti-angiogenic targeted drug and the world's only approved endostatin product, has been included in the NRDL since 2017. It has become one of the cornerstone treatments for advanced non-small cell lung cancer.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}